Crossmark

Activating a B cell immune response regresses immunologically cold tumours

Crossref DOI link: https://doi.org/10.1038/s41565-026-02170-9

Published Online: 2026-06-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Aggarwal, Heena https://orcid.org/0000-0002-4535-3497
Gupta, Nimish https://orcid.org/0000-0002-9857-1025
Sengupta, Aniruddha https://orcid.org/0000-0001-5560-0837
Sarkar, Arindam https://orcid.org/0000-0002-5946-2846
Mylavarapu, Sanghamitra https://orcid.org/0000-0002-8249-095X
Pires, Ivan S. https://orcid.org/0000-0002-4035-0027
Saha, Tanmoy

Sarkar, Binayak https://orcid.org/0009-0009-3366-4851
Kulkarni, Ashish https://orcid.org/0000-0002-5713-2202
Mahajan, Vinay S. https://orcid.org/0000-0003-0814-2989
Goyal, Lipika https://orcid.org/0000-0002-9777-6221
Bardia, Aditya https://orcid.org/0000-0003-4885-1157
Fahrner, Richard

Gherardi, Ermanno

Mashelkar, Raghunath https://orcid.org/0009-0008-3112-4774
Soon-Shiong, Patrick

Jang, Hae Lin https://orcid.org/0000-0003-3923-9732
Sengupta, Shiladitya https://orcid.org/0000-0002-8065-5052
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA293908)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA276525)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA236702)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (K00CA274651)
License Information

Text and Data Mining valid from 2026-06-12

Version of Record valid from 2026-06-12
More Information

Article History

Received: 19 May 2024

Accepted: 31 March 2026

First Online: 12 June 2026

Competing interests

: A.B., R.F., E.G., P.S.-S., R.M. and S.S. hold equity and consult in Alyssum Therapeutics. N.G., A. Sengupta, A. Sarkar, R.F. and S.S. are listed as inventors on patents covering AT-1965 licensed to Alyssum Therapeutics. L.G. is a PI on a clinical study funded by Alyssum Therapeutics. I.S.P., T.S., B.S., A.K. and V.S.M. declare no competing interests. H.L.J. is a founder and has a financial interest in Qilin Bio Inc. H.L.J.’s interests were reviewed and are managed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict of interest policies.

Document is current

Any future updates will be listed below